BR112022019795A2 - Polipeptídeo de ligação a antígeno que se liga a cd47 e uso deste - Google Patents

Polipeptídeo de ligação a antígeno que se liga a cd47 e uso deste

Info

Publication number
BR112022019795A2
BR112022019795A2 BR112022019795A BR112022019795A BR112022019795A2 BR 112022019795 A2 BR112022019795 A2 BR 112022019795A2 BR 112022019795 A BR112022019795 A BR 112022019795A BR 112022019795 A BR112022019795 A BR 112022019795A BR 112022019795 A2 BR112022019795 A2 BR 112022019795A2
Authority
BR
Brazil
Prior art keywords
antigen
binds
binding polypeptide
polypeptide
binding
Prior art date
Application number
BR112022019795A
Other languages
English (en)
Inventor
Gui Qiu
Zhu Hong
Wang Liangliang
Zhang Xiaoyun
Zou Xiaofang
Shen Hengqiao
Xu Hongjiang
Yang Ling
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of BR112022019795A2 publication Critical patent/BR112022019795A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

POLIPEPTÍDEO DE LIGAÇÃO A ANTÍGENO QUE SE LIGA A CD47 E USO DESTE. São fornecidos um polipeptídeo de ligação ao antígeno que se liga a CD47 ou uma porção de ligação ao antígeno deste e um ácido nucleico, vetor, célula ou composição farmacêutica que codifica o polipeptídeo. O polipeptídeo pode reduzir um tumor ou inibir o crescimento de células tumorais, tratar câncer, promover fagocitose de macrófagos e semelhantes.
BR112022019795A 2020-04-02 2021-04-01 Polipeptídeo de ligação a antígeno que se liga a cd47 e uso deste BR112022019795A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010255615 2020-04-02
PCT/CN2021/084802 WO2021197401A1 (zh) 2020-04-02 2021-04-01 结合cd47的抗原结合多肽及用途

Publications (1)

Publication Number Publication Date
BR112022019795A2 true BR112022019795A2 (pt) 2022-11-16

Family

ID=77927419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019795A BR112022019795A2 (pt) 2020-04-02 2021-04-01 Polipeptídeo de ligação a antígeno que se liga a cd47 e uso deste

Country Status (10)

Country Link
EP (1) EP4130042A1 (pt)
JP (1) JP2023519620A (pt)
KR (1) KR20220163991A (pt)
CN (1) CN115190887A (pt)
AU (1) AU2021250200A1 (pt)
BR (1) BR112022019795A2 (pt)
CA (1) CA3177519A1 (pt)
IL (1) IL296829A (pt)
TW (1) TW202144407A (pt)
WO (1) WO2021197401A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118076644A (zh) * 2021-09-30 2024-05-24 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体
CN118055947A (zh) * 2021-09-30 2024-05-17 正大天晴药业集团南京顺欣制药有限公司 联合治疗血液肿瘤的抗cd47抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP4349868A2 (en) 2010-05-14 2024-04-10 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
BR112015013431A2 (pt) * 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
JP6909153B2 (ja) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
TW201819413A (zh) * 2016-11-28 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EP3845561A4 (en) * 2018-08-31 2022-07-06 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-CD47 ANTIBODIES AND ITS USE
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途

Also Published As

Publication number Publication date
WO2021197401A1 (zh) 2021-10-07
EP4130042A1 (en) 2023-02-08
KR20220163991A (ko) 2022-12-12
CN115190887A (zh) 2022-10-14
TW202144407A (zh) 2021-12-01
IL296829A (en) 2022-11-01
AU2021250200A1 (en) 2022-12-01
CA3177519A1 (en) 2021-10-07
WO2021197401A8 (zh) 2021-11-04
JP2023519620A (ja) 2023-05-11

Similar Documents

Publication Publication Date Title
BR112022019795A2 (pt) Polipeptídeo de ligação a antígeno que se liga a cd47 e uso deste
BR112021011431A2 (pt) Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
Chatterjee et al. Protein paucimannosylation is an enriched N‐glycosylation signature of human cancers
PE20181953A1 (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
BR112019011582A2 (pt) anticorpos e métodos de utilização dos mesmos
CR20220317A (es) Anticuerpos anti-cd73 y usos de estos
EA201992613A1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение
BR112023000826A2 (pt) Anticorpo anti-ctla-4 e uso do mesmo
PE20191531A1 (es) Combinaciones fungicidas
BR112022010069A2 (pt) Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica
BR112022000876A2 (pt) Anticorpos imunomoduladores e métodos de uso destes
BR112019005129A2 (pt) anticorpos anti-pd-1
BR112021020867A2 (pt) Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
BR112022018995A2 (pt) Composições para higiene pessoal
BR112022001359A2 (pt) Método e composição para anticorpos anti-cd73 e variantes
MX2021012003A (es) Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos.
BR112021024003A2 (pt) Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
BR112022021426A2 (pt) Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73
BR112022009570A2 (pt) Anticorpo anti-¿v¿6 isolado ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-¿v¿6 ou fragmento de ligação ao antígeno, para produção de um conjugado anticorpo anti-¿v¿6-fármaco e para tratamento de câncer em um indivíduo, e, composição farmacêutica
BR112022020256A2 (pt) “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
BR9909805A (pt) Certos inibidores de tiol de enzima de conversão de endotelina
BR112023018948A2 (pt) Edição multiplex com enzimas cas
BR112023019138A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso
BR112018016798A2 (pt) anticorpo ou fragmento de anticorpo específico, composição de ácido nucleico, composição de vetor, célula, e composição farmacêutica